Preparation, characterization and in vivo pharmacokinetic study of ginsenoside Rb1-PLGA nanoparticles

• Published in: Scientific reports Vol. 13; no. 1; p. 18472
• Main Authors: Du, Lixin, Lu, Huiling, Xiao, Yifei, Guo, Zhihua, Li, Ya
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 27.10.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/154; 631/45; 639/925; 692/308; Bioavailability; Drug delivery; Evaporation; Ginsenosides; Humanities and Social Sciences; multidisciplinary; Nanoparticles; Pharmacokinetics; Polylactide-co-glycolide; Science; Science (multidisciplinary); Zeta potential
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-45858-x

This study aimed to construct a Ginsenoside Rb1-PLGA nano drug delivery system, optimize its preparation process, characterize and evaluate the resulting Ginsenoside Rb1-PLGA Nanoparticles (GRb1@PLGA@NPs). GRb1@PLGA@NPs were prepared using the emulsion solvent evaporation method. The optimal preparation process was determined using Plackett–Burman design combined with Box-Behnken experiments. Physical characterization and in vitro release studies were conducted. LC–MS/MS technique was employed to investigate the pharmacokinetic characteristics of GRb1 and GRb1@PLGA@NPs in rat plasma. The optimal preparation process yielded GRb1@PLGA@NPs with a particle size of 120.63 nm, polydispersity index (PDI) of 0.172, zeta potential of − 22.67 mV, encapsulation efficiency of 75%, and drug loading of 11%. In vitro release demonstrated sustained drug release. Compared to GRb1, GRb1@PLGA@NPs exhibited a shortened time to peak concentration by approximately 0.72-fold. The area under the plasma concentration–time curve significantly increased to 4.58-fold of GRb1. GRb1@PLGA@NPs formulated using the optimal process exhibited uniform distribution and stable quality, its relative oral bioavailability was significantly improved compared to free GRb1.